We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-3.39%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$9.1B
AUM Growth
-$787M
Cap. Flow
+$233M
Cap. Flow %
2.56%
Top 10 Hldgs %
30.12%
Holding
189
New
31
Increased
28
Reduced
27
Closed
17

Top Buys

Rank Stock Value
1
IVVD icon
Invivyd
IVVD
+$200M
2
ZBH icon
Zimmer Biomet
ZBH
+$100M
3
BIIB icon
Biogen
BIIB
+$54.7M
4
HCA icon
HCA Healthcare
HCA
+$47.4M
5
MREO
Mereo BioPharma
MREO
+$45.7M

Top Sells

Rank Stock Value
1
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$78.7M
2
ASND icon
Ascendis Pharma A/S
ASND
+$58.9M
3
NTRA icon
Natera
NTRA
+$55.6M
4
ELV icon
Elevance Health
ELV
+$48.9M
5
BSX icon
Boston Scientific
BSX
+$48.1M

Sector Composition

Rank Sector Weight
1 Healthcare 95.35%
2 Technology 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OBIO icon
151
Orchestra BioMed
OBIO
$235M
$4.95M 0.05%
500,000
– –
SGHT icon
152
Sight Sciences
SGHT
$291M
$4.54M 0.05%
+200,000
New +$6.57M
RGEN icon
153
Repligen
RGEN
$6.98B
$4.25M 0.05%
+14,724
New +$3.78M
LABP
154
DELISTED
Landos Biopharma, Inc. Common Stock
LABP
$4.13M 0.05%
28,322
-39,778
-58% -$5.16M
ADAG
155
Adagene
ADAG
$251M
$3.95M 0.04%
275,000
– –
CABA icon
156
Cabaletta Bio
CABA
$429M
$3.68M 0.04%
+302,509
New +$2.79M
SNDX icon
157
Syndax Pharmaceuticals
SNDX
$1.7B
$3.64M 0.04%
+190,600
New +$3.18M
ASLN
158
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$3.51M 0.04%
49,250
-13,750
-22% -$1.56M
INZY
159
DELISTED
Inozyme Pharma
INZY
$3.41M 0.04%
294,000
+105,296
+56% +$1.64M
TRML
160
DELISTED
Tourmaline Bio
TRML
$3.35M 0.04%
24,724
– –
TARA icon
161
Protara Therapeutics
TARA
$215M
$3.11M 0.03%
450,000
– –
IFRX icon
162
InflaRx
IFRX
$247M
$2.76M 0.03%
1,064,118
– –
SBBP
163
DELISTED
Strongbridge Biopharma plc.
SBBP
$1.62M 0.02%
794,675
-949,994
-54% -$2.21M
LBPH
164
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
$1M 0.01%
113,500
– –
KZR
165
CALL
DELISTED
Kezar Life Sciences
KZR
$980K 0.01%
+11,340
New +$751K
MAPSW
166
CALL
DELISTED
WM TECHNOLOGY INC WTS
MAPSW
$649K 0.01%
150,200
– –
PHAS
167
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$551K 0.01%
+177,113
New +$591K
APTX
168
DELISTED
Aptinyx Inc. Common Stock
APTX
$359K ﹤0.01%
+153,285
New +$391K
AZN icon
169
CALL
AstraZeneca
AZN
$269B
$312K ﹤0.01%
+2,600
New +$303K
OWLT.WS
170
CALL
DELISTED
Owlet, Inc. Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50
OWLT.WS
$207K ﹤0.01%
+220,704
New +$225K
ALEC icon
171
Alector
ALEC
$170M
– –
-611,478
Closed -$12.7M
ARCT icon
172
Arcturus Therapeutics
ARCT
$161M
– –
-848,503
Closed -$28.7M
ASND icon
173
Ascendis Pharma A/S
ASND
$16.6B
– –
-447,859
Closed -$58.9M
AUPH icon
174
Aurinia Pharmaceuticals
AUPH
$1.93B
– –
-6,069,032
Closed -$78.7M
BSX icon
175
CALL
Boston Scientific
BSX
$68.6B
– –
-250,000
Closed -$10.7M
4 5 6
7
8

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q3 2021 Portfolio in Review

As of Q3 2021, OrbiMed held 189 positions worth $9.1B, down 8% from $9.89B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

OrbiMed's Q3 2021 filing shows 31 new, 28 increased, 27 reduced and 17 closed positions. Its largest new stake was Invivyd: 5,383,500 shares worth $227M. The largest sale was Aurinia Pharmaceuticals, an estimated $78.7M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 95% a quarter earlier, followed by Technology.

  • OrbiMed's largest Q3 2021 buy was Invivyd: 5,383,500 shares worth $227M.
  • OrbiMed added most to Biogen in Q3 2021, an estimated $54.7M increase.
  • OrbiMed's biggest Q3 2021 reduction was Natera, cutting an estimated $55.6M.
  • OrbiMed fully exited Aurinia Pharmaceuticals in Q3 2021, selling an estimated $78.7M.
  • OrbiMed's ten largest holdings make up 30% of its $9.1B portfolio in Q3 2021.
  • OrbiMed opened 31 new positions and closed 17 in Q3 2021.
  • OrbiMed's portfolio value fell 8% quarter-over-quarter to $9.1B.

Based on OrbiMed's 13F filing for Q3 2021, filed 15 Nov 2021.